Literature DB >> 15528713

Effects of intrapartum penicillin prophylaxis on intestinal bacterial colonization in infants.

Françoise Jauréguy1, Mathieu Carton, Pierre Panel, Pierre Foucaud, Marie-José Butel, Florence Doucet-Populaire.   

Abstract

Early-onset group B streptococcal (GBS) infections remain a leading cause of morbidity and mortality in infants. To prevent the vertical transmission of GBS and neonatal GBS infection, guidelines recommend intrapartum penicillin or amoxicillin prophylaxis. This intrapartum antibiotic prophylaxis (IAP) is suspected to favor colonization by antibiotic-resistant bacteria. However, the effects of this prophylaxis on the patterns of acquisition of gastrointestinal bacterial flora in infants have never been studied. We collected stool samples from 3-day-old infants born to mothers who received intrapartum amoxicillin (antibiotic-exposed group; n = 25) and to untreated mothers (non-antibiotic-exposed group; n = 25). The groups were matched for factors known to affect intestinal microbial colonization: gestational age, type of delivery, and type of feeding. Qualitative and quantitative differential analyses of the bacterial flora in stool samples were performed. Similar numbers of infants in the non-antibiotic-exposed and antibiotic-exposed groups were colonized by aerobic bacteria and amoxicillin-resistant enterobacteria (75 and 77%, respectively) (P = 0.79). In contrast, significantly fewer infants in the antibiotic-exposed group than in the non-antibiotic-exposed group were colonized by anaerobic bacteria, especially Clostridium (12 and 40%, respectively) (P < 0.05). Regarding intestinal bacterial colonization, the differences between antibiotic-exposed and non-antibiotic-exposed infants were remarkably few. The only statistically significant effect was the reduced initial bacterial colonization by Clostridium in the antibiotic-exposed group. In our study, the use of IAP did not favor colonization by beta-lactam-resistant bacteria. However, further evaluations are required to highlight the potential risks of the widespread use of antibiotics to prevent early-onset GBS infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528713      PMCID: PMC525278          DOI: 10.1128/JCM.42.11.5184-5188.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Intrapartum antibiotic prophylaxis 1: relative effects of recommended antibiotics on gram-negative pathogens.

Authors:  Rodney K Edwards; Penny Clark; Christopher L Sistrom; Patrick Duff
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

Review 2.  Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis.

Authors:  Matthew R Moore; Stephanie J Schrag; Anne Schuchat
Journal:  Lancet Infect Dis       Date:  2003-04       Impact factor: 25.071

3.  Early-onset neonatal sepsis in the era of group B streptococcal prevention.

Authors:  R S Baltimore; S M Huie; J I Meek; A Schuchat; K L O'Brien
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

4.  Susceptibility of Enterobacteriaceae to beta-lactam agents and fluoroquinolones: a 3-year survey in France.

Authors:  J Sirot; M H Nicolas-Chanoine; H Chardon; J L Avril; C Cattoen; J C Croix; H Dabernat; T Fosse; J C Ghnassia; E Lecaillon; A Marmonier; M Roussel-Delvallez; C J Soussy; A Trevoux; F Vandenesch; C Dib; N Moniot-Ville; Y Rezvani
Journal:  Clin Microbiol Infect       Date:  2002-04       Impact factor: 8.067

Review 5.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

6.  Perinatal antibiotic usage and changes in colonization and resistance rates of group B streptococcus and other pathogens.

Authors:  Renee Spaetgens; Kim DeBella; Doreen Ma; Sheila Robertson; Melissa Mucenski; H Dele Davies
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

7.  Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants.

Authors:  Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole
Journal:  N Engl J Med       Date:  2002-07-25       Impact factor: 91.245

8.  Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta.

Authors:  Terri B Hyde; Tami M Hilger; Arthur Reingold; Monica M Farley; Katherine L O'Brien; Anne Schuchat
Journal:  Pediatrics       Date:  2002-10       Impact factor: 7.124

9.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.

Authors:  Stephanie Schrag; Rachel Gorwitz; Kristi Fultz-Butts; Anne Schuchat
Journal:  MMWR Recomm Rep       Date:  2002-08-16

10.  Antepartum use of antibiotics and early-onset neonatal sepsis: the next 4 years.

Authors:  Craig V Towers; Gerald G Briggs
Journal:  Am J Obstet Gynecol       Date:  2002-08       Impact factor: 8.661

View more
  21 in total

1.  Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis.

Authors:  U Parm; T Metsvaht; E Sepp; M-L Ilmoja; H Pisarev; M Pauskar; I Lutsar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-06       Impact factor: 3.267

2.  Pharmacokinetics of penicillin g in very-low-birth-weight neonates.

Authors:  Tuuli Metsvaht; Kersti Oselin; Mari-Liis Ilmoja; Kaili Anier; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

3.  Evaluation of the Cepheid Xpert GBS assay for rapid detection of group B Streptococci in amniotic fluids from pregnant women with premature rupture of membranes.

Authors:  Nadege Bourgeois-Nicolaos; Anne-Gael Cordier; Christelle Guillet-Caruba; François Casanova; Alexandra Benachi; Florence Doucet-Populaire
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

Review 4.  The Neonatal Microbiome and Its Partial Role in Mediating the Association between Birth by Cesarean Section and Adverse Pediatric Outcomes.

Authors:  Diana Montoya-Williams; Dominick J Lemas; Lisa Spiryda; Keval Patel; O'neshia Olivia Carney; Josef Neu; Tiffany L Carson
Journal:  Neonatology       Date:  2018-05-22       Impact factor: 4.035

Review 5.  Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Clin Microbiol Rev       Date:  2018-08-15       Impact factor: 26.132

Review 6.  The population genetics of commensal Escherichia coli.

Authors:  Olivier Tenaillon; David Skurnik; Bertrand Picard; Erick Denamur
Journal:  Nat Rev Microbiol       Date:  2010-03       Impact factor: 60.633

Review 7.  The infant microbiome development: mom matters.

Authors:  Noel T Mueller; Elizabeth Bakacs; Joan Combellick; Zoya Grigoryan; Maria G Dominguez-Bello
Journal:  Trends Mol Med       Date:  2014-12-11       Impact factor: 11.951

8.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 9.  Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.

Authors:  Caná L Ross; Jennifer K Spinler; Tor C Savidge
Journal:  Anaerobe       Date:  2016-05-12       Impact factor: 3.331

10.  Maternal group B Streptococcus and the infant gut microbiota.

Authors:  A E Cassidy-Bushrow; A Sitarik; A M Levin; S V Lynch; S Havstad; D R Ownby; C C Johnson; G Wegienka
Journal:  J Dev Orig Health Dis       Date:  2015-08-12       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.